Nevertheless, given their overarching effects on tumour immunity, acting upstream of the main effector type 2 cytokines IL-4, IL-5, IL-9, and IL-13 and T cells, the prospect of therapeutically targeting these cytokines is promising. The gene discussed is IL5; the disease is neoplasm.